Table 2.

Correlation Between Natural Killer Cell CD107a, CD16, and Interferon γ Expression in Response to Plate-Bound Ebola Virus Glycoprotein (GP) Plus Post-Dose 1 (Visit 1) and Post-Dose 2 (Visit 2) Serum and Anti-GP Antibody Concentration According to Vaccine Regimen Group^a

Visit by Group	R 2 (P Value)b
	CD107a (%)	CD16 (MFI)	IFN-γ (%)
Visit 1
Group 1 (d 29)	0.129 (.21)c	0.00292 (.85)c	0.0214 (.60)c
Group 2 (d 57)	0.00469 (.82)c	0.0193 (.62)c	0.00638 (.78)c
Group 3 (d 29)	0.480 (.006)	0.550 (.002)	0.553 (.002)
Group 4 (d 57)	0.0924 (.29)c	0.312 (.04)	0.248 (.07)c
Group 5 (d 15)	0.394 (.052)c	0.221 (.17)c	0.397 (.051)c
Visit 2
Group 1 (d 50)	0.0209 (.61)c	0.00775 (.76)c	0.00144 (.89)c
Group 2 (d 78)	0.0639 (.36)c	0.0339 (.51)c	0.0895 (.28)c
Group 3 (d 50)	0.660 (<.001)	0.554 (.002)	0.531 (.003)
Group 4 (d 78)	0.364 (.02)	0.612 (<.001)	0.327 (.03)
Group 5 (d 36)	0.859 (<.001)	0.690 (.003)	0.276 (.12)c

Abbreviations: IFN, interferon; MFI, mean fluorescence intensity.

^aAntiglycoprotein antibody concentrations were determined previously by Milligan et al [21].

^b R ² values determined by means of linear regression. Significance was defined as P < .05.

^cNonsignificant correlations.